Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI vs CIP in Severe Autoimmune Encephalitis
NCT03542279Completed
- Sponsor
- Xuanwu Hospital
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of intravenous immunoglobulin G in Autoimmune Encephalitis (AE) (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Proportion of patients achieving functional improvement at 3 months. Started Nov 2020; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT03542279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542279.